Larimar Therapeutics, Inc. (LRMR) stock
LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.23+0.23 (+7.86%)
Close on Nov 18, 2026Market cap $335.02MP/E –Yield –
Larimar Therapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Larimar Therapeutics's shares outstanding was 78M at Sep 30, 2025. For fiscal 2024 it was 61M, up 39.5% from the year before. Over ten years it grew 17.5% a year on average. The highest annual figure on record is 61M in fiscal 2024.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 61M | +39.5% |
| FY2023 | Dec 31, 2023 | 44M | +70.4% |
| FY2022 | Dec 31, 2022 | 26M | +50.1% |
| FY2021 | Dec 31, 2021 | 17M | +44.4% |
| FY2020 | Dec 31, 2020 | 12M | +95.1% |
| FY2019 | Dec 31, 2019 | 6M | -81.1% |
| FY2018 | Dec 31, 2018 | 32M | +17.5% |
| FY2017 | Dec 31, 2017 | 27M | +0.5% |
| FY2016 | Dec 31, 2016 | 27M | +2.0% |
| FY2015 | Dec 31, 2015 | 27M | +119.5% |
| FY2014 | Dec 31, 2014 | 12M | +1572.0% |
| FY2013 | Dec 31, 2013 | 1M | +2.7% |
| FY2012 | Dec 31, 2012 | 1M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | 78M | +22.8% |
| Q2 FY2025 | Jun 30, 2025 | 64M | +0.4% |
| Q1 FY2025 | Mar 31, 2025 | 64M | +19.4% |
| Q4 FY2024 | Dec 31, 2024 | 64M | +45.4% |
| Q3 FY2024 | Sep 30, 2024 | 64M | +45.3% |
| Q2 FY2024 | Jun 30, 2024 | 64M | +45.3% |
| Q1 FY2024 | Mar 31, 2024 | 54M | +22.0% |
| Q4 FY2023 | Dec 31, 2023 | 44M | -0.4% |
| Q3 FY2023 | Sep 30, 2023 | 44M | +97.5% |
| Q2 FY2023 | Jun 30, 2023 | 44M | +139.4% |
| Q1 FY2023 | Mar 31, 2023 | 44M | +139.4% |
| Q4 FY2022 | Dec 31, 2022 | 44M | +140.3% |
| Q3 FY2022 | Sep 30, 2022 | 22M | +21.5% |
| Q2 FY2022 | Jun 30, 2022 | 18M | +14.6% |
| Q1 FY2022 | Mar 31, 2022 | 18M | +14.6% |
| Q4 FY2021 | Dec 31, 2021 | 18M | +14.6% |
| Q3 FY2021 | Sep 30, 2021 | 18M | +14.4% |
| Q2 FY2021 | Jun 30, 2021 | 16M | +70.5% |
| Q1 FY2021 | Mar 31, 2021 | 16M | +162.6% |
| Q4 FY2020 | Dec 31, 2020 | 16M | -57.2% |
| Q3 FY2020 | Sep 30, 2020 | 16M | +162.4% |
| Q2 FY2020 | Jun 30, 2020 | 9M | +54.0% |
| Q1 FY2020 | Mar 31, 2020 | 6M | -83.7% |
| Q4 FY2019 | Dec 31, 2019 | 37M | +0.9% |
| Q3 FY2019 | Sep 30, 2019 | 6M | -83.4% |
| Q2 FY2019 | Jun 30, 2019 | 6M | -77.9% |
| Q1 FY2019 | Mar 31, 2019 | 37M | +35.5% |
| Q4 FY2018 | Dec 31, 2018 | 37M | +34.7% |
| Q3 FY2018 | Sep 30, 2018 | 37M | +33.2% |
| Q2 FY2018 | Jun 30, 2018 | 28M | +0.6% |
| Q1 FY2018 | Mar 31, 2018 | 28M | +0.7% |
| Q4 FY2017 | Dec 31, 2017 | 27M | +0.6% |
| Q3 FY2017 | Sep 30, 2017 | 27M | +0.6% |
| Q2 FY2017 | Jun 30, 2017 | 27M | – |
| Q1 FY2017 | Mar 31, 2017 | 27M | – |
| Q4 FY2016 | Dec 31, 2016 | 27M | – |
| Q3 FY2016 | Sep 30, 2016 | 27M | – |
See a number that looks wrong?